Loading organizations...
Genextra is a private biotechnology holding company and venture capital firm based in Milan, Italy, that primarily invests in early-stage European life science and medical technology enterprises. The organization specifically targets the research and development of innovative therapeutics, advanced diagnostic tools, and specialized nanotechnology applications for healthcare. Genextra has built a diverse investment portfolio that features recognizable biotechnology and pharmaceutical companies such as Tethis, Intercept Pharmaceuticals, and Nouscom. Although the firm's total assets under management currently remain undisclosed, its majority shareholder recently acted as the anchor investor for XGEN Venture's €160 million life science fund. Additionally, the firm previously supported a €3 million capital increase for Tethis alongside co-investor Atlante Ventures. Genextra was founded in 2003 by a consortium of Italian entrepreneurs and scientists led by Francesco Micheli, Piergiuseppe Pelicci, and Umberto Veronesi.
Key people at Genextra.
Genextra has 3 tracked investments across 3 companies. The latest tracked deal is $55.0M Series C in InnovHeart in January 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 27, 2022 | InnovHeart | $55.0M Series C | Grand Pharmaceutical Group | Indaco Venture Partners, Panakes Partners |
| Apr 1, 2018 | Erydel | $32.0M Series B | Soffinova Partners | Innogest |
| Aug 1, 2012 | Intercept Pharmaceuticals | $30.0M Series C | OrbiMed | Atlas Venture |
Key people at Genextra.
